Skip to main content
Have a personal or library account? Click to login
Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia Cover

Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia

Radiology and Oncology
Volume 58 (2024): Issue 4 (December 2024)
By: Ajda Drofenik,  Ales Blinc,  Mojca Bozic Mijovski,  Tadej Pajic,  Matjaz Vrtovec and  Matjaz Sever  
Open Access
|Oct 2024
Figures & tables

Figures & Tables

FIGURE 1.

Change in JAK2 V617F mutation burden and Agatston coronary calcium score over the 4-year observation period in patients whose JAK2 V617F mutation burden increased (left-side columns) and in patients whose mutation burden decreased (right-side columns). Bar charts represent the mean mutation burden (%), and line graphs represent the median Agatston coronary calcium score.

Baseline characteristics of patients with JAK2 V617F positive essential thromocythemia (ET) and of control group at the first visit and at the second visit (body mass index, BMI)

FIRST VISITSECOND VISITPatient groupControl group
First vs. second visitFirst vs. second visit
Patient groupControl groupp-valuePatient groupControl groupp-valuep-valuep-value
Age (years)55.11 (13.40)59.07 (12.02)0.18658.36 (13.44)62.08 (11.99)0.214--
Sex (M/F)12/2414/240.81112/2414/240.754--
BMI (kg/m2)25.22 (3.65)27.27 (4.64)0.03826.13 (4.66)27.54 (4.60)0.1950.0210.184
Waist (cm)
  Male94.6 (11.1)102.2 (10.4)0.08698.4 (11.2)104.0 (12.7)0.2600.0140.201
  Female89.5 (9.1)89.3 (14.2)0.96593.1 (11.1)93.6 (15.0)0.8990.0860.005
Systolic blood pressure (mmHg)140 (22)134 (14)0.219144 (19)141 (20)0.6150.1340.018
Diastolic blood pressure (mmHg)81 (9)82 (11)0.87086 (12)89 (10)0.2470.044< 0.001
Smoking 0.267 0.4030.8920.924
  Current5/363/38 4/363/38
  Former10/366/38 12/368/38

Coronary calcium burden expressed as Agatston score of patients with JAK2 V617F positive essential thromocythemia (ET) and control subjects at the first visit and at the fourth-year follow-up visit and the correlation with JAK2 V617F allele burden for the ET patient group

FIRST VISITSECOND VISITPatient group First vs. second visitControl group First vs. second visitCorrelation with JAK2 V617F allele burden, p-value
Patient groupControl groupp-valuePatient groupControl groupp-valuep-valuep-valueFirst visitSecond visit
Agatston score0 (0–8.6)0 (0–8.6)0.5250.6 (0–40.3)2.6 (0–30.1)0.9540.009< 0.0010.1910.069
Calcium burden LM0 (0–0)0 (0–0)0.3590 (0–1.2)0 (0–0)0.2740.0140.9530.7000.657
Calcium burden LAD0 (0–2.7)0 (0–2.68)0.5810 (0–32.5)0 (0–21.3)0.8610.435< 0.0010.2430.069
Calcium burden LCX0 (0–0)0 (0–0)0.6300 (0–0)0 (0–0)0.8250.2080.2040.4330.074
Calcium burden RCA0 (0–0)0 (0–0)0.2450 (0–0.8)0 (0–0)0.6760.0740.0120.7000.045

Laboratory parameters of patients with JAK2 V617F positive essential thromocythemia (ET) and of the control group at the second visit after 4-year follow-up_ Means and standard deviations are given for the normally distributed data, medians and interquartile range are given for non-normally distributed data

THE SECOND VISITET PATIENTS (n = 36)CONTROL GROUP (n = 38)COMPARISON BETWEEN GROUPS (p-value)
2Glucose (mmol/l)5.00 (4.60–5.40)5.00 (4.70–5.60)0.565
2Creatinine (μmol/l)76.10 (63.85–85.85)71.30 (62.45–83.55)0.351
1Total cholesterol (mmol/l)5.00 (1.05)5.33 (0.93)0.163
1HDL-cholesterol (mmol/l)1.45 (0.59)1.66 (0.53)0.118
1LDL-cholesterol (mmol/l)2.66 (0.89)2.94 (0.82)0.168
1Triglycerides (mmol/l)1.97 (0.89)1.61 (0.80)0.850
1Leukocytes (109/L)7.86 (2.83)6.54 (1.63)0.016
1Red blood cells (1012/L)4.42 (0.69)4.84 (0.42)0.002
1Haemoglobinb133 (15)145 (12)0.001
1Platelets (109/L)524.56 (218.67)250.38 (60.05)< 0.001
1Lymphocytes (109/L)1.88 (0.90)2.02 (0.72)0.195
1Mixed cells (109/L)0.71 (0.29)0.59 (0.20)0.067
1Neutrophils (109/L)4.81 (1.97)3.93 (1.31)0.031
1IL-1 (ng/L)43.26 (4.98)34.59 (6.48)< 0.001
1IL-8 (ng/L)28.89 (8.45)20.64 (9.51)< 0.001
1P-selectin (ug/L)76.24 (19.54)43.33 (13.36)< 0.001
1VCAM-1 (mg/L)1.17 (0.52)0.72 (0.26)< 0.001
2IL-6 (ng/L)8.70 (7.70–9.38)6.80 (6.28–7.40)< 0.001
2IL-10 (ng/L)5.65 (0.33–9.35)5.25 (0.00–7.90)0.417
1TNFa (ng/L)43.90 (7.34)37.60 (9.15)0.002
2VWF-A2 (ng/L)231.50 (199.25–256.25)195.00 (167.50–213.00)< 0.001
2hs-CRP (mg/L)0.87 (0.50–2.16)0.91 (0.55–4.43)0.314
DOI: https://doi.org/10.2478/raon-2024-0036 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 565 - 572
Submitted on: Mar 24, 2024
Accepted on: Jun 1, 2024
Published on: Oct 4, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
essential thrombocythemia,
JAK2 V617F mutation,
JAK2 V617F allele burden,
coronary calcium score
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2024 Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec, Matjaz Sever, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 58 (2024): Issue 4 (December 2024)
Previous article
Next article